Loading clinical trials...
Loading clinical trials...
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of the Safety and Efficacy of orBec® (Oral Beclomethasone 17,21-Dipropionate)in Conjunction With Ten Days of High-Dose Prednisone Therapy in the Treatment of Patients With Gastrointestinal GVHD
Conditions
Interventions
oral beclomethasone 17,21-dipropionate
Placebo
Locations
3
United States
Buffalo, New York, United States
Durham, North Carolina, United States
Seattle, Washington, United States
Start Date
October 1, 2009
Primary Completion Date
December 1, 2011
Completion Date
May 1, 2012
Last Updated
December 6, 2013
Lead Sponsor
Soligenix
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions